Sitagliptin vs Insulin Glargine: side-by-side comparison
Sitagliptin (DPP-4 inhibitor) and Insulin Glargine (Long-acting insulin analogue) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Sitagliptin | Insulin Glargine |
|---|---|---|
| Therapeutic class | DPP-4 inhibitor | Long-acting insulin analogue |
| CAS | 486460-32-6 | 160337-95-1 |
| ATC | A10BH01 | A10AE04 |
| Molecular weight | 407.31 g/mol | 6063 Da |
| Brands with this active ingredient | 1 | 1 |
What they share
Sitagliptin and Insulin Glargine share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Sitagliptin acts by a different mechanism than Insulin Glargine, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Sitagliptin: Sitagliptin reversibly inhibits DPP-4, the serine protease responsible for rapid degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Insulin Glargine: Insulin glargine binds the insulin receptor with similar affinity to human insulin, activating intracellular signalling that increases glucose uptake in muscle and adipose tissue, suppresses hepatic glucose production an…
Indications compared
Sitagliptin: Sitagliptin is approved in adults with type 2 diabetes mellitus, alone or in combination with other antidiabetic agents, to improve glycaemic control. Insulin Glargine: Insulin glargine is approved as basal insulin therapy in adults and paediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus when oral or non-insulin injectable therapy is insufficien…
Safety profile
Sitagliptin: Sitagliptin is generally well tolerated. Insulin Glargine: Hypoglycaemia is the most important adverse effect of any insulin and can be severe in case of missed meals, prolonged exercise, alcohol intake or interaction with other glucose-lowering agents.
Frequently asked questions
Is Sitagliptin better than Insulin Glargine? ▾
Sitagliptin and Insulin Glargine are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Sitagliptin and Insulin Glargine be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Sitagliptin
Products with Insulin Glargine
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.